A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas

Oncologist

Volumn 18, Issue 3, 2013, Pages 271-272

  Uronis, Hope E ^a   Bendell, Johanna C ^b   Altomare, Ivy ^a   Blobe, Gerard C ^a   David Hsu, S ^a   Morse, Michael A ^a   Pang, Herbert ^a   Yousuf Zafar, S ^a   Conkling, Paul ^c   Favaro, Justin ^d   Arrowood, Christy C ^a   Cushman, Stephanie M ^a   Meadows, Kellen L ^a   Brady, John C ^a   Nixon, Andrew B ^a   Hurwitz, Herbert I ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c Virginia Oncology Associates   (United States)

^d PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; NEUROPILIN 1; NEUROPILIN 2; OXALIPLATIN;

ANOREXIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; METASTASIS; OVERALL SURVIVAL; PERFORATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FISTULA; STOMACH ADENOCARCINOMA; VEIN THROMBOSIS;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FLUOROURACIL; HUMANS; ORGANOPLATINUM COMPOUNDS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84875412388     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0404     Document Type: Article

References (0)